Skip to content

Phenotyping Asthma for Bronchial Thermoplasty

Phenotyping Asthma for Bronchial Thermoplasty: Airway Smooth Muscle Structure and Function

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03435237
Enrollment
50
Registered
2018-02-15
Start date
2021-05-10
Completion date
2024-12-31
Last updated
2024-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Asthma

Keywords

Optical Coherence Tomography, Bronchial Thermoplasty

Brief summary

This study will evaluate a new imaging technology, called optical coherence tomography (OCT) to examine the asthmatic airways before and after bronchial thermoplasty, which is a new treatment option for severe asthmatic patients. The aim of this study is to learn more about how airways respond to this new treatment. In the future the investigators hope OCT will aid clinicians in the initial assessment, management and long-term follow up of patients receiving bronchial thermoplasty.

Detailed description

Asthma currently affects over 300 million individuals worldwide and the number of the affected patient is continuously increasing. Approximately 10% of asthmatics have poorly controlled, severe symptoms. The exact mechanisms behind the development of asthma are unknown. However, the excessive contraction of airway smooth muscle leading to airway constriction is thought to be responsible for the majority of the symptoms of asthma. A new treatment option, termed bronchial thermoplasty, can offer relief for individuals with severe asthma. Bronchial thermoplasty works by reducing smooth muscle with thermal energy. This new imaging technology, called optical coherence tomography (OCT) is the first imaging modality that is capable to visualize airway smooth muscle in humans. In this study the investigators will examine the asthmatic airways before and after bronchial thermoplasty to learn about how airways respond to this treatment. The long term goal of this study is to use OCT to look at the airways with the hope of helping clinicians monitor and predict the response to bronchial thermoplasty. During the scheduled bronchial thermoplasty procedure, OCT imaging will be performed. The study imaging will add less than 10 minutes to the time required for the standard procedure.Twelve months following the completion of bronchial thermoplasty, the investigators will ask the participants to return to the hospital to undergo follow-up tests including a CT scan and a bronchoscopy procedure with repeat OCT imaging. The investigators expect these test to be accomplished in 2 additional visits.

Interventions

None listed

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Patient undergoing elective bronchial thermoplasty 2. Patient is between the ages of 18 and 60 3. Patient is able to give informed consent 4. Negative pregnancy test for all female of childbearing potential who are sexually active and not using contraception, are seeking to become pregnant, or who are nursing. 5. Nonsmoking (\<5 pack year tobacco exposure) 6. No history of co-existing lung disease 7. Meet American Thoracic Society criteria for diagnosis of asthma with either/or 1. Bronchodilator response to albuterol (≥12% change in FEV1) 2. Positive methacholine bronchoprovocation (PC20 \< 25 mg/ml)

Exclusion criteria

1. Patients who are pregnant. 2. Patient does not meet the requirements to undergo clinical bronchial thermoplasty, as determined by the treating physician

Design outcomes

Primary

MeasureTime frameDescription
Evaluate OCT for assessing bronchial thermoplasty1 yearDoes OCT imaging detect biomarkers that may predict patient's clinical response to bronchial thermoplasty as assessed by the Asthma Quality of Life Questionnaire.

Countries

United States

Contacts

Primary ContactMelissa J Suter, PhD
msuter@mgh.harvard.edu617-724-7691

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026